Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOHIT NARANG

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1881695351
CMS profile
39457
Location
OWING MILLS, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$211,304.24

211 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 211 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOHIT NARANG

NPI 1881695351 · CMS profile ID 39457

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

OWING MILLS, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 211 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1881695351?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOHIT NARANG, NPI 1881695351, CMS profile ID 39457. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 211 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881695351?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MOHIT NARANG, NPI 1881695351, CMS profile ID 39457. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 211 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881695351?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MOHIT NARANG, NPI 1881695351, CMS profile ID 39457, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 211 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1881695351?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

211 matching records · $211,304.24 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 211 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 211.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Pharmacosmos Therapeutics Inc. $156.4910/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959145021 CMS
Pharmacosmos Therapeutics Inc. $49.2010/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959145017 CMS
PFIZER INC. $18.6210/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949313481 CMS
Takeda Pharmaceuticals U.S.A., Inc. $154.7010/01/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955749629 CMS
Daiichi Sankyo Inc. $3,880.0009/29/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930865061 CMS
E.R. Squibb & Sons, L.L.C. $114.0809/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932713141 CMS
E.R. Squibb & Sons, L.L.C. $1,337.3609/29/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932713155 CMS
Daiichi Sankyo Inc. $100.0109/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930864305 CMS
Daiichi Sankyo Inc. $684.1709/27/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930865631 CMS
Celgene Corporation $29.3009/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932713137 CMS
Rigel Pharmaceuticals, Inc. $20.8509/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962278477 CMS
Takeda Pharmaceuticals U.S.A., Inc. $639.0509/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955749625 CMS
E.R. Squibb & Sons, L.L.C. $4,310.0009/14/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932713153 CMS
GlaxoSmithKline, LLC. $2,000.0009/13/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944370001 CMS
ABBVIE INC. $18.9609/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891233929 CMS
Eli Lilly and Company $2,187.5009/06/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918232367 CMS
Alexion Pharmaceuticals, Inc. $18.6409/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915318791 CMS
E.R. Squibb & Sons, L.L.C. $114.0308/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932713151 CMS
Takeda Pharmaceuticals U.S.A., Inc. $24.1708/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955749621 CMS
BeiGene USA, Inc. $231.4508/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964379409 CMS
Incyte Corporation $21.6108/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943022023 CMS
Pharmacosmos Therapeutics Inc. $7,026.0708/22/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959145011 CMS
Myovant Sciences Inc. $24.3908/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941227963 CMS
Daiichi Sankyo Inc. $29.7708/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930823201 CMS
Astellas Pharma US Inc $20.9708/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940248027 CMS
Celgene Corporation $21.8908/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932713099 CMS
E.R. Squibb & Sons, L.L.C. $4,310.0008/10/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932713127 CMS
Genentech USA, Inc. $26.3208/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950703607 CMS
Rigel Pharmaceuticals, Inc. $109.9708/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962275331 CMS
E.R. Squibb & Sons, L.L.C. $17.3508/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932713103 CMS
E.R. Squibb & Sons, L.L.C. $4,310.0008/04/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932713113 CMS
Rigel Pharmaceuticals, Inc. $55.0008/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962282103 CMS
Janssen Biotech, Inc. $21.0408/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886011089 CMS
Novartis Pharmaceuticals Corporation $18.3908/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894014653 CMS
Rigel Pharmaceuticals, Inc. $20.0008/03/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962282353 CMS
Janssen Biotech, Inc. $18.8508/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886011095 CMS
Janssen Biotech, Inc. $1,767.5008/01/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886011049 CMS
Rigel Pharmaceuticals, Inc. $270.9607/29/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962281987 CMS
E.R. Squibb & Sons, L.L.C. $10.1607/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932713097 CMS
E.R. Squibb & Sons, L.L.C. $599.0007/27/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932713117 CMS
E.R. Squibb & Sons, L.L.C. $111.5207/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932713121 CMS
Novartis Pharmaceuticals Corporation $12.9407/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894014649 CMS
E.R. Squibb & Sons, L.L.C. $803.9807/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932713107 CMS
E.R. Squibb & Sons, L.L.C. $69.7207/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932713109 CMS
Takeda Pharmaceuticals U.S.A., Inc. $825.0007/21/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955749617 CMS
Genentech USA, Inc. $21.1907/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950710661 CMS
Janssen Biotech, Inc. $550.0007/18/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886011043 CMS
PFIZER INC. $21.1907/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949204811 CMS
Pharmacosmos Therapeutics Inc. $359.2007/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959145007 CMS
BeiGene USA, Inc. $359.0307/13/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940796157 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $119,254.47 174
PY2020 $86,122.88 95
PY2021 $154,257.27 134
PY2022 $211,304.24 211
PY2023 $196,200.02 268
PY2024 $234,124.45 297
PY2025 $290,678.66 350

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $167,355.52 109
PY2024 Principal investigator $313,750.73 145
PY2023 Principal investigator $513,428.13 200
PY2022 Principal investigator $363,274.38 157
PY2021 Principal investigator $468,059.94 253
PY2020 Principal investigator $710,998.15 224
PY2019 Recipient $11,416.00 2
PY2019 Principal investigator $902,480.27 205

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

109 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $4,500.00 12/29/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549098
Principal investigator 1 Karyopharm Therapeutics Inc. $191.00 12/03/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663830
Principal investigator 1 Karyopharm Therapeutics Inc. $95.00 12/03/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663842
Principal investigator 1 Karyopharm Therapeutics Inc. $1,844.90 12/03/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663854
Principal investigator 1 Karyopharm Therapeutics Inc. $191.00 12/03/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663858
Principal investigator 1 Karyopharm Therapeutics Inc. $95.00 12/03/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663876
Principal investigator 1 Karyopharm Therapeutics Inc. $191.00 12/03/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663878
Principal investigator 1 Karyopharm Therapeutics Inc. $215.00 12/03/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663882
Principal investigator 1 Karyopharm Therapeutics Inc. $95.00 12/03/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663886
Principal investigator 1 Karyopharm Therapeutics Inc. $215.00 12/03/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663888
Principal investigator 1 Karyopharm Therapeutics Inc. $95.00 12/03/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663892
Principal investigator 1 Karyopharm Therapeutics Inc. $191.00 12/03/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663894
Principal investigator 1 Karyopharm Therapeutics Inc. $191.00 12/03/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663900
Principal investigator 1 Karyopharm Therapeutics Inc. $215.00 12/03/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663912
Principal investigator 1 Karyopharm Therapeutics Inc. $95.00 12/03/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663926
Principal investigator 1 Incyte Corporation $1,600.00 11/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549104
Principal investigator 1 Incyte Corporation $1,600.00 11/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549109
Principal investigator 1 Incyte Corporation $1,600.00 11/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549117
Principal investigator 1 Incyte Corporation $1,600.00 11/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549123
Principal investigator 1 Incyte Corporation $1,600.00 11/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549129
Principal investigator 1 Incyte Corporation $1,600.00 11/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549135
Principal investigator 1 Incyte Corporation $1,600.00 11/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549141
Principal investigator 1 Incyte Corporation $200.00 11/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549159
Principal investigator 1 Celgene Corporation $5,851.00 10/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, Pa
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1222304541
Principal investigator 1 Incyte Corporation $956.00 10/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549147
Principal investigator 1 Incyte Corporation $956.00 10/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) No dispute reported 06/30/2026 1240549153
Principal investigator 1 Karyopharm Therapeutics Inc. $95.00 10/02/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663816
Principal investigator 1 Karyopharm Therapeutics Inc. $215.00 10/02/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663822
Principal investigator 1 Karyopharm Therapeutics Inc. $215.00 10/02/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663824
Principal investigator 1 Karyopharm Therapeutics Inc. $95.00 10/02/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663828
Principal investigator 1 Karyopharm Therapeutics Inc. $215.00 10/02/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663836
Principal investigator 1 Karyopharm Therapeutics Inc. $191.00 10/02/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663846
Principal investigator 1 Karyopharm Therapeutics Inc. $191.00 10/02/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663848
Principal investigator 1 Karyopharm Therapeutics Inc. $1,844.90 10/02/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663852
Principal investigator 1 Karyopharm Therapeutics Inc. $2,516.00 10/02/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663856
Principal investigator 1 Karyopharm Therapeutics Inc. $215.00 10/02/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663860
Principal investigator 1 Karyopharm Therapeutics Inc. $215.00 10/02/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663864
Principal investigator 1 Karyopharm Therapeutics Inc. $215.00 10/02/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663870
Principal investigator 1 Karyopharm Therapeutics Inc. $1,844.90 10/02/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663874
Principal investigator 1 Karyopharm Therapeutics Inc. $191.00 10/02/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663884
Principal investigator 1 Karyopharm Therapeutics Inc. $95.00 10/02/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663896
Principal investigator 1 Karyopharm Therapeutics Inc. $191.00 10/02/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663904
Principal investigator 1 Karyopharm Therapeutics Inc. $191.00 10/02/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663908
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $88.99 09/30/2025 Non-covered Recipient Entity
Maryland Oncology Hematology Columbia
A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-4) No dispute reported 06/30/2026 1235996099
Principal investigator 1 Incyte Corporation $1,600.00 09/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549045
Principal investigator 1 Incyte Corporation $1,600.00 09/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549062
Principal investigator 1 Incyte Corporation $1,600.00 09/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549068
Principal investigator 1 Incyte Corporation $1,600.00 09/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549074
Principal investigator 1 Incyte Corporation $100.00 09/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549081
Principal investigator 1 Incyte Corporation $125.00 09/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549087
Principal investigator 1 Incyte Corporation $666.00 09/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549092
Principal investigator 1 Karyopharm Therapeutics Inc. $191.00 09/04/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663832
Principal investigator 1 Karyopharm Therapeutics Inc. $215.00 09/04/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663880
Principal investigator 1 Karyopharm Therapeutics Inc. $1,488.65 09/04/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663898
Principal investigator 1 Karyopharm Therapeutics Inc. $215.00 08/04/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663818
Principal investigator 1 Karyopharm Therapeutics Inc. $215.00 08/04/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663820
Principal investigator 1 Karyopharm Therapeutics Inc. $95.00 08/04/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663834
Principal investigator 1 Karyopharm Therapeutics Inc. $191.00 08/04/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663838
Principal investigator 1 Karyopharm Therapeutics Inc. $215.00 08/04/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663844
Principal investigator 1 Karyopharm Therapeutics Inc. $1,488.65 08/04/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663862
Principal investigator 1 Karyopharm Therapeutics Inc. $1,938.95 08/04/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663866
Principal investigator 1 Karyopharm Therapeutics Inc. $191.00 08/04/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663868
Principal investigator 1 Karyopharm Therapeutics Inc. $191.00 08/04/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663890
Principal investigator 1 Karyopharm Therapeutics Inc. $95.00 08/04/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663906
Principal investigator 1 Karyopharm Therapeutics Inc. $191.00 08/04/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663910
Principal investigator 1 Karyopharm Therapeutics Inc. $215.00 08/04/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663914
Principal investigator 1 Genmab U.S., Inc. $1,000.00 07/25/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235931067
Principal investigator 1 Incyte Corporation $956.00 07/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549050
Principal investigator 1 Incyte Corporation $956.00 07/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) No dispute reported 06/30/2026 1240549056
Principal investigator 1 Karyopharm Therapeutics Inc. $4,997.95 07/03/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663826
Principal investigator 1 Karyopharm Therapeutics Inc. $95.00 07/03/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663850
Principal investigator 1 Karyopharm Therapeutics Inc. $191.00 07/03/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663872
Principal investigator 1 Karyopharm Therapeutics Inc. $62.00 07/03/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663916
Principal investigator 1 Karyopharm Therapeutics Inc. $2,516.00 07/03/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663918
Principal investigator 1 Karyopharm Therapeutics Inc. $1,479.15 07/03/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663922
Principal investigator 1 Karyopharm Therapeutics Inc. $215.00 07/03/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663924
Principal investigator 1 Celgene Corporation $15,224.48 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1222305604
Principal investigator 1 Incyte Corporation $125.00 06/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549003
Principal investigator 1 Incyte Corporation $476.00 06/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549026
Principal investigator 1 Incyte Corporation $476.00 06/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549032
Principal investigator 1 Incyte Corporation $125.00 06/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549038
Principal investigator 1 Celgene Corporation $1,500.00 05/21/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, Pa
Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. No dispute reported 06/30/2026 1222304521
Principal investigator 1 Novocure Inc. $1,000.00 05/08/2025 Non-covered Recipient Entity
US Oncology Research, LLC
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 1250856471
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,310.00 04/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, Pa
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS 986205 in Participants with Muscle-Invasive Bladder Cancer No dispute reported 06/30/2026 1235996087
Principal investigator 1 Incyte Corporation $956.00 04/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) No dispute reported 06/30/2026 1240549008
Principal investigator 1 Incyte Corporation $956.00 04/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549014
Principal investigator 1 Incyte Corporation $956.00 04/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240549020
Principal investigator 1 Novocure Inc. $850.00 04/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 1250856653
Principal investigator 1 Novocure Inc. $1,000.00 04/11/2025 Non-covered Recipient Entity
US Oncology Research, LLC
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 1250856749
Principal investigator 1 Hoffmann-La Roche Limited $1,125.00 03/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
BLU667 1101 ARROW ongoing No dispute reported 06/30/2026 1211681216
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $19,689.00 03/17/2025 Non-covered Recipient Entity
Us Oncology Res Llc
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS 986205 in Participants with Muscle-Invasive Bladder Cancer No dispute reported 06/30/2026 1235992203
Principal investigator 1 Incyte Corporation $476.00 03/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240548956
Principal investigator 1 Incyte Corporation $125.00 03/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240548961
Principal investigator 1 Incyte Corporation $125.00 03/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240548967
Principal investigator 1 Incyte Corporation $861.00 03/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240548985
Principal investigator 1 Karyopharm Therapeutics Inc. $5,261.00 03/06/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663902
Principal investigator 1 Hoffmann-La Roche Limited $235.00 02/07/2025 Non-covered Recipient Entity
US Oncology Research, LLC
BLU667 1101 ARROW ongoing No dispute reported 06/30/2026 1211681210
Principal investigator 1 Mirati Therapeutics, Inc. $4,500.00 02/03/2025 Non-covered Recipient Entity
Us Oncology Res Llc
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236530290
Principal investigator 1 Celgene Corporation $20,400.00 01/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1222305586
Principal investigator 1 Karyopharm Therapeutics Inc. $2,516.00 01/20/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663840
Principal investigator 1 Karyopharm Therapeutics Inc. $445.00 01/20/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663920
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,620.00 01/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, Pa
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS 986205 in Participants with Muscle-Invasive Bladder Cancer No dispute reported 06/30/2026 1235996085
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $13,210.00 01/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, Pa
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1235996089
Principal investigator 1 Incyte Corporation $956.00 01/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240548973
Principal investigator 1 Incyte Corporation $956.00 01/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) No dispute reported 06/30/2026 1240548978
Principal investigator 1 Incyte Corporation $125.00 01/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240548990
Principal investigator 1 Incyte Corporation $666.00 01/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240548996
Principal investigator 1 Novocure Inc. $850.00 01/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 1250856313
Principal investigator 1 Genmab U.S., Inc. $3,957.00 01/09/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235931063